PRASAD SUYASH (CMO and Head of R&D) reported 1 transaction at TAYSHA GENE THERAPIES, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 9/30/2020ACC: 0001209191-20-052463
Officer· CMO and Head of R&D
Since Sep 2020
+315.00
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
3.84K acquired · 3.53K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
+3.84K
Price / share
—
Trade value
—
% of position
0.6%
9/28/2020
668.75K→672.59K
Total
Net shares
+3.84K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/28/2020 | C · Conversion | +3.84K | — | — | 0.6% | 668.75K | 672.59K |
| Total | +3.84K | $0.00 | ||||||
Derivative Transactions1
Series B Preferred Stock
Direct
Converts to
Common Stock
3.84K shares
Shares
−3.53K
Strike price
Held after
0.00
Exercisable
—
9/28/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series B Preferred Stock Direct | Common Stock3.84K shares | 9/28/2020 | C · Conversion | −3.53K | — | 0.00 |